Earnings Preview: BLCO to Report Financial Results Pre-market on February 19
Top Gap Ups and Downs on Thursday: PM, HON, RBLX and More
Bausch Health Cut to Hold by Jefferies Over B+L Update
Sector Update: Health Care Stocks Retreat Thursday Afternoon
Sector Update: Health Care
Bausch + Lomb Shares Down 8%, Says It Won't Go Private at This Time
Express News | Bausch Health To Continue To Own Its 88% Interest In Bausch + Lomb; Says Process Did Not Lead To An Offer That Reflected Bausch + Lomb's Value
Express News | Bausch + Lomb Says Full Separation Remains The Goal; Says Process Of Taking Company Private Will Not Result In A Transaction At This Time
Bausch + Lomb Provides Update on Potential Sale
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $18
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Cuts Target Price to $22
RBC Trims Price Target on Bausch + Lomb to $22 From $23, Keeps Outperform Rating
Express News | Bausch + Lomb : Stifel Cuts Target Price to $18 From $19
Morgan Stanley Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Maintains Target Price $19
Improved Revenues Required Before Bausch + Lomb Corporation (NYSE:BLCO) Shares Find Their Feet
Bausch + Lomb to Announce 2024 Financial Results
Press Release: Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $19